| Abstract | High dose intravenous methylprednisolone treatment is effective and safe in the treatment of relapses in multiple sclerosis, but the long term effects are unclear. Pharmacokinetics are almost unknown, but may be very important for the understanding of the clinical and paraclinical effects. In view of what is known now, IVMP should have a prominent place in basic and clinical MS research. |
| Authors | O R Hommes, F Barkhof, P J Jongen, S T Frequin
(Affiliation: Institute of Neurology, University Hospital Nijmegan, The Netherlands.)
|
| Journal | Multiple sclerosis (Houndmills, Basingstoke, England)
(Mult Scler)
Vol. 1
Issue 6
Pg. 327-8
(Jul 1996)
ISSN: 1352-4585 ENGLAND |
| PMID | 9345410
(Publication Type: Journal Article, Review)
|
| Chemical References |
|
| Topics |
- Dose-Response Relationship, Drug
- Forecasting
- Humans
- Methylprednisolone
(adverse effects, pharmacokinetics, therapeutic use)
- Multiple Sclerosis
(drug therapy)
- Treatment Outcome
|
